<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39340081</PMID><DateRevised><Year>2024</Year><Month>09</Month><Day>30</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2076-393X</ISSN><JournalIssue CitedMedium="Print"><Volume>12</Volume><Issue>9</Issue><PubDate><Year>2024</Year><Month>Sep</Month><Day>14</Day></PubDate></JournalIssue><Title>Vaccines</Title><ISOAbbreviation>Vaccines (Basel)</ISOAbbreviation></Journal><ArticleTitle>Hybrid Immunity against SARS-CoV-2 Variants: A Narrative Review of the Literature.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">1051</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/vaccines12091051</ELocationID><Abstract><AbstractText>The emergence of SARS-CoV-2 led to a global health crisis and the burden of the disease continues to persist. The rapid development and emergency authorization of various vaccines, including mRNA-based vaccines, played a pivotal role in mitigating severe illness and mortality. However, rapid viral mutations, leading to several variants of concern, challenged vaccine effectiveness, particularly concerning immune evasion. Research on immunity, both from natural infection and vaccination, revealed that while neutralizing antibodies provide protection against infection, their effect is short-lived. The primary defense against severe COVID-19 is derived from the cellular immune response. Hybrid immunity, developed from a combination of natural infection and vaccination, offers enhanced protection, with convalescent vaccinated individuals showing significantly higher levels of neutralizing antibodies. As SARS-CoV-2 continues to evolve, understanding the durability and breadth of hybrid immunity becomes crucial. This narrative review examines the latest data on humoral and cellular immunity from both natural infection and vaccination, discussing how hybrid immunity could inform and optimize future vaccination strategies in the ongoing battle against COVID-19 and in fear of a new pandemic.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tsagkli</LastName><ForeName>Panagiota</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Immunobiology and Vaccinology Research Laboratory and Infectious Diseases Department "MAKKA", First Department of Paediatrics, "Aghia Sophia" Children's Hospital, Athens Medical School, 11527 Athens, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Geropeppa</LastName><ForeName>Maria</ForeName><Initials>M</Initials><Identifier Source="ORCID">0009-0002-5059-6191</Identifier><AffiliationInfo><Affiliation>Immunobiology and Vaccinology Research Laboratory and Infectious Diseases Department "MAKKA", First Department of Paediatrics, "Aghia Sophia" Children's Hospital, Athens Medical School, 11527 Athens, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Papadatou</LastName><ForeName>Ioanna</ForeName><Initials>I</Initials><Identifier Source="ORCID">0000-0003-0421-9416</Identifier><AffiliationInfo><Affiliation>Immunobiology and Vaccinology Research Laboratory and Infectious Diseases Department "MAKKA", First Department of Paediatrics, "Aghia Sophia" Children's Hospital, Athens Medical School, 11527 Athens, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Spoulou</LastName><ForeName>Vana</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Immunobiology and Vaccinology Research Laboratory and Infectious Diseases Department "MAKKA", First Department of Paediatrics, "Aghia Sophia" Children's Hospital, Athens Medical School, 11527 Athens, Greece.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Vaccines (Basel)</MedlineTA><NlmUniqueID>101629355</NlmUniqueID><ISSNLinking>2076-393X</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">COVID-19 immunology</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2 vaccination</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2 variants</Keyword><Keyword MajorTopicYN="N">hybrid immunity</Keyword></KeywordList><CoiStatement>The authors declare no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>8</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>9</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>22</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>22</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>1</Hour><Minute>31</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>14</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39340081</ArticleId><ArticleId IdType="pmc">PMC11436074</ArticleId><ArticleId IdType="doi">10.3390/vaccines12091051</ArticleId><ArticleId IdType="pii">vaccines12091051</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Number of COVID-19 Cases Reported to WHO.  [(accessed on 24 June 2024)].  Available online:  https://data.who.int/dashboards/covid19/cases?n=c.</Citation></Reference><Reference><Citation>COVID-19 Vaccines with WHO Emergency Use Listing.  [(accessed on 1 June 2024)].  Available online:  https://extranet.who.int/prequal/vaccines/covid-19-vaccines-who-emergency-use-listing.</Citation></Reference><Reference><Citation>Heinz F.X., Stiasny K. Distinguishing features of current COVID-19 vaccines: Knowns and unknowns of antigen presentation and modes of action. Npj Vaccines. 2021;6:104. doi: 10.1038/s41541-021-00369-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41541-021-00369-6</ArticleId><ArticleId IdType="pmc">PMC8368295</ArticleId><ArticleId IdType="pubmed">34400651</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeng B., Gao L., Zhou Q., Yu K., Sun F. Effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern: A systematic review and meta-analysis. BMC Med. 2022;20:200. doi: 10.1186/s12916-022-02397-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12916-022-02397-y</ArticleId><ArticleId IdType="pmc">PMC9126103</ArticleId><ArticleId IdType="pubmed">35606843</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang Z.-R., Jiang Y.-W., Li F.-X., Liu D., Lin T.-F., Zhao Z.-Y., Wei C., Jin Q.-Y., Li X.-M., Jia Y.-X., et al. Efficacy of SARS-CoV-2 vaccines and the dose–response relationship with three major antibodies: A systematic review and meta-analysis of randomised controlled trials. Lancet Microbe. 2023;4:e236–e246. doi: 10.1016/S2666-5247(22)00390-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2666-5247(22)00390-1</ArticleId><ArticleId IdType="pmc">PMC9974155</ArticleId><ArticleId IdType="pubmed">36868258</ArticleId></ArticleIdList></Reference><Reference><Citation>Sette A., Crotty S. Adaptive immunity to SARS-CoV-2 and COVID-19. Cell. 2021;184:861–880. doi: 10.1016/j.cell.2021.01.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2021.01.007</ArticleId><ArticleId IdType="pmc">PMC7803150</ArticleId><ArticleId IdType="pubmed">33497610</ArticleId></ArticleIdList></Reference><Reference><Citation>Niessl J., Sekine T., Buggert M. T cell immunity to SARS-CoV-2. Semin. Immunol. 2021;55:101505. doi: 10.1016/j.smim.2021.101505.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.smim.2021.101505</ArticleId><ArticleId IdType="pmc">PMC8529278</ArticleId><ArticleId IdType="pubmed">34711489</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Z., Muecksch F., Schaefer-Babajew D., Finkin S., Viant C., Gaebler C., Hoffmann H.-H., Barnes C.O., Cipolla M., Ramos V., et al. Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection. Nature. 2021;595:426–431. doi: 10.1038/s41586-021-03696-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03696-9</ArticleId><ArticleId IdType="pmc">PMC8277577</ArticleId><ArticleId IdType="pubmed">34126625</ArticleId></ArticleIdList></Reference><Reference><Citation>Laidlaw B.J., Ellebedy A.H. The germinal centre B cell response to SARS-CoV-2. Nat. Rev. Immunol. 2021;22:7–18. doi: 10.1038/s41577-021-00657-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41577-021-00657-1</ArticleId><ArticleId IdType="pmc">PMC8647067</ArticleId><ArticleId IdType="pubmed">34873279</ArticleId></ArticleIdList></Reference><Reference><Citation>Gudbjartsson D.F., Norddahl G.L., Melsted P., Gunnarsdottir K., Holm H., Eythorsson E., Arnthorsson A.O., Helgason D., Bjarnadottir K., Ingvarsson R.F., et al. Humoral Immune Response to SARS-CoV-2 in Iceland. N. Engl. J. Med. 2020;383:1724–1734. doi: 10.1056/NEJMoa2026116.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2026116</ArticleId><ArticleId IdType="pmc">PMC7494247</ArticleId><ArticleId IdType="pubmed">32871063</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaebler C., Wang Z., Lorenzi J.C.C., Muecksch F., Finkin S., Tokuyama M., Cho A., Jankovic M., Schaefer-Babajew D., Oliveira T.Y., et al. Evolution of antibody immunity to SARS-CoV-2. Nature. 2021;591:639–644. doi: 10.1038/s41586-021-03207-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03207-w</ArticleId><ArticleId IdType="pmc">PMC8221082</ArticleId><ArticleId IdType="pubmed">33461210</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanyal M., Chansaenroj J., Yorsaeng R., Puenpa J., Wanlapakorn N., Chirathaworn C., Sudhinaraset N., Sripramote M., Chalongviriyalert P., Jirajariyavej S., et al. Long-term persistence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein-specific and neutralizing antibodies in recovered COVID-19 patients. PLoS ONE. 2022;17:e0267102. doi: 10.1371/journal.pone.0267102.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0267102</ArticleId><ArticleId IdType="pmc">PMC9022880</ArticleId><ArticleId IdType="pubmed">35446889</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen K.W., Linderman S.L., Moodie Z., Czartoski J., Lai L., Mantus G., Norwood C., Nyhoff L.E., Edara V.V., Floyd K., et al. Longitudinal analysis shows durable and broad immune memory after SARS-CoV-2 infection with persisting antibody responses and memory B and T-cells. Cell Rep. Med. 2021;2:100354. doi: 10.1016/j.xcrm.2021.100354.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.xcrm.2021.100354</ArticleId><ArticleId IdType="pmc">PMC8253687</ArticleId><ArticleId IdType="pubmed">34250512</ArticleId></ArticleIdList></Reference><Reference><Citation>Li C., Lee A., Grigoryan L., Arunachalam P.S., Scott M.K.D., Trisal M., Wimmers F., Sanyal M., Weidenbacher P.A., Feng Y., et al. Mechanisms of innate and adaptive immunity to the Pfizer-BioNTech BNT162b2 vaccine. Nat. Immunol. 2022;23:543–555. doi: 10.1038/s41590-022-01163-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-022-01163-9</ArticleId><ArticleId IdType="pmc">PMC8989677</ArticleId><ArticleId IdType="pubmed">35288714</ArticleId></ArticleIdList></Reference><Reference><Citation>Kannenberg J., Trawinski H., Henschler R., Buhmann R., Hönemann M., Jassoy C. Antibody Course and Memory B-Cell Response in the First Year After Severe Acute Respiratory Syndrome Coronavirus 2 Infection. J. Infect. Dis. 2022;226:664–672. doi: 10.1093/infdis/jiac034.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiac034</ArticleId><ArticleId IdType="pmc">PMC8903334</ArticleId><ArticleId IdType="pubmed">35104869</ArticleId></ArticleIdList></Reference><Reference><Citation>Papadatou I., Tzovara I., Licciardi P. The Role of Serotype-Specific Immunological Memory in Pneumococcal Vaccination: Current Knowledge and Future Prospects. Vaccines. 2019;7:13. doi: 10.3390/vaccines7010013.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines7010013</ArticleId><ArticleId IdType="pmc">PMC6466264</ArticleId><ArticleId IdType="pubmed">30700048</ArticleId></ArticleIdList></Reference><Reference><Citation>Sokal A., Chappert P., Barba-Spaeth G., Roeser A., Fourati S., Azzaoui I., Vandenberghe A., Fernandez I., Meola A., Bouvier-Alias M., et al. Maturation and persistence of the anti-SARS-CoV-2 memory B cell response. Cell. 2021;184:1201–1213.e1214. doi: 10.1016/j.cell.2021.01.050.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2021.01.050</ArticleId><ArticleId IdType="pmc">PMC7994111</ArticleId><ArticleId IdType="pubmed">33571429</ArticleId></ArticleIdList></Reference><Reference><Citation>Sakharkar M., Rappazzo C.G., Wieland-Alter W.F., Hsieh C.-L., Wrapp D., Esterman E.S., Kaku C.I., Wec A.Z., Geoghegan J.C., McLellan J.S., et al. Prolonged evolution of the human B cell responseto SARS-CoV-2 infection. Sci. Immunol. 2021;6:eabg6916. doi: 10.1126/sciimmunol.abg6916.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciimmunol.abg6916</ArticleId><ArticleId IdType="pmc">PMC8128290</ArticleId><ArticleId IdType="pubmed">33622975</ArticleId></ArticleIdList></Reference><Reference><Citation>Marcotte H., Piralla A., Zuo F., Du L., Cassaniti I., Wan H., Kumagai-Braesh M., Andréll J., Percivalle E., Sammartino J.C., et al. Immunity to SARS-CoV-2 up to 15 months after infection. iScience. 2022;25:103743. doi: 10.1016/j.isci.2022.103743.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.isci.2022.103743</ArticleId><ArticleId IdType="pmc">PMC8736281</ArticleId><ArticleId IdType="pubmed">35018336</ArticleId></ArticleIdList></Reference><Reference><Citation>Notarbartolo S., Ranzani V., Bandera A., Gruarin P., Bevilacqua V., Putignano A.R., Gobbini A., Galeota E., Manara C., Bombaci M., et al. Integrated longitudinal immunophenotypic, transcriptional, and repertoire analyses delineateimmune responses in patients with COVID-19. Sci. Immunol. 2021;6:eabg5021. doi: 10.1126/sciimmunol.abg5021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciimmunol.abg5021</ArticleId><ArticleId IdType="pubmed">34376481</ArticleId></ArticleIdList></Reference><Reference><Citation>Le Bert N., Tan A.T., Kunasegaran K., Tham C.Y.L., Hafezi M., Chia A., Chng M.H.Y., Lin M., Tan N., Linster M., et al. SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls. Nature. 2020;584:457–462. doi: 10.1038/s41586-020-2550-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2550-z</ArticleId><ArticleId IdType="pubmed">32668444</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodda L.B., Netland J., Shehata L., Pruner K.B., Morawski P.A., Thouvenel C.D., Takehara K.K., Eggenberger J., Hemann E.A., Waterman H.R., et al. Functional SARS-CoV-2-Specific Immune Memory Persists after Mild COVID-19. Cell. 2021;184:169–183.e117. doi: 10.1016/j.cell.2020.11.029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.11.029</ArticleId><ArticleId IdType="pmc">PMC7682481</ArticleId><ArticleId IdType="pubmed">33296701</ArticleId></ArticleIdList></Reference><Reference><Citation>Sekine T., Perez-Potti A., Rivera-Ballesteros O., Strålin K., Gorin J.-B., Olsson A., Llewellyn-Lacey S., Kamal H., Bogdanovic G., Muschiol S., et al. Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19. Cell. 2020;183:158–168.e114. doi: 10.1016/j.cell.2020.08.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.08.017</ArticleId><ArticleId IdType="pmc">PMC7427556</ArticleId><ArticleId IdType="pubmed">32979941</ArticleId></ArticleIdList></Reference><Reference><Citation>Peng Y., Mentzer A.J., Liu G., Yao X., Yin Z., Dong D., Dejnirattisai W., Rostron T., Supasa P., Liu C., et al. Broad and strong memory CD4+ and CD8+ T-cells induced by SARS-CoV-2 in UK convalescent individuals following COVID-19. Nat. Immunol. 2020;21:1336–1345. doi: 10.1038/s41590-020-0782-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-020-0782-6</ArticleId><ArticleId IdType="pmc">PMC7611020</ArticleId><ArticleId IdType="pubmed">32887977</ArticleId></ArticleIdList></Reference><Reference><Citation>Rydyznski Moderbacher C., Ramirez S.I., Dan J.M., Grifoni A., Hastie K.M., Weiskopf D., Belanger S., Abbott R.K., Kim C., Choi J., et al. Antigen-Specific Adaptive Immunity to SARS-CoV-2 in Acute COVID-19 and Associations with Age and Disease Severity. Cell. 2020;183:996–1012.e1019. doi: 10.1016/j.cell.2020.09.038.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.09.038</ArticleId><ArticleId IdType="pmc">PMC7494270</ArticleId><ArticleId IdType="pubmed">33010815</ArticleId></ArticleIdList></Reference><Reference><Citation>Breton G., Mendoza P., Hägglöf T., Oliveira T.Y., Schaefer-Babajew D., Gaebler C., Turroja M., Hurley A., Caskey M., Nussenzweig M.C. Persistent cellular immunity to SARS-CoV-2 infection. J. Exp. Med. 2021;218:e20202515. doi: 10.1084/jem.20202515.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20202515</ArticleId><ArticleId IdType="pmc">PMC7845919</ArticleId><ArticleId IdType="pubmed">33533915</ArticleId></ArticleIdList></Reference><Reference><Citation>Wragg K.M., Lee W.S., Koutsakos M., Tan H.-X., Amarasena T., Reynaldi A., Gare G., Konstandopoulos P., Field K.R., Esterbauer R., et al. Establishment and recall of SARS-CoV-2 spike epitope-specific CD4+ T cell memory. Nat. Immunol. 2022;23:768–780. doi: 10.1038/s41590-022-01175-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-022-01175-5</ArticleId><ArticleId IdType="pubmed">35314848</ArticleId></ArticleIdList></Reference><Reference><Citation>Sattler A., Angermair S., Stockmann H., Heim K.M., Khadzhynov D., Treskatsch S., Halleck F., Kreis M.E., Kotsch K. SARS–CoV-2–specific T cell responses and correlations with COVID-19 patient predisposition. J. Clin. Investig. 2020;130:6477–6489. doi: 10.1172/JCI140965.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI140965</ArticleId><ArticleId IdType="pmc">PMC7685725</ArticleId><ArticleId IdType="pubmed">32833687</ArticleId></ArticleIdList></Reference><Reference><Citation>Zuo J., Dowell A.C., Pearce H., Verma K., Long H.M., Begum J., Aiano F., Amin-Chowdhury Z., Hoschler K., Brooks T., et al. Robust SARS-CoV-2-specific T cell immunity is maintained at 6 months following primary infection. Nat. Immunol. 2021;22:620–626. doi: 10.1038/s41590-021-00902-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-021-00902-8</ArticleId><ArticleId IdType="pmc">PMC7610739</ArticleId><ArticleId IdType="pubmed">33674800</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y., Zeng Q., Deng C., Li M., Li L., Liu D., Liu M., Ruan X., Mei J., Mo R., et al. Robust induction of B cell and T cell responses by a third dose of inactivated SARS-CoV-2 vaccine. Cell Discov. 2022;8:10. doi: 10.1038/s41421-022-00373-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41421-022-00373-7</ArticleId><ArticleId IdType="pmc">PMC8803973</ArticleId><ArticleId IdType="pubmed">35102140</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Q., Bastard P., Karbuz A., Gervais A., Tayoun A.A., Aiuti A., Belot A., Bolze A., Gaudet A., Bondarenko A., et al. Human genetic and immunological determinants of critical COVID-19 pneumonia. Nature. 2022;603:587–598. doi: 10.1038/s41586-022-04447-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-04447-0</ArticleId><ArticleId IdType="pmc">PMC8957595</ArticleId><ArticleId IdType="pubmed">35090163</ArticleId></ArticleIdList></Reference><Reference><Citation>Natalini A., Simonetti S., Sher C., D’Oro U., Hayday A.C., Di Rosa F. Durable CD8 T Cell Memory against SARS-CoV-2 by Prime/Boost and Multi-Dose Vaccination: Considerations on Inter-Dose Time Intervals. Int. J. Mol. Sci. 2022;23:14367. doi: 10.3390/ijms232214367.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms232214367</ArticleId><ArticleId IdType="pmc">PMC9698736</ArticleId><ArticleId IdType="pubmed">36430845</ArticleId></ArticleIdList></Reference><Reference><Citation>Rijkers G.T., Weterings N., Obregon-Henao A., Lepolder M., Dutt T.S., van Overveld F.J., Henao-Tamayo M. Antigen Presentation of mRNA-Based and Virus-Vectored SARS-CoV-2 Vaccines. Vaccines. 2021;9:848. doi: 10.3390/vaccines9080848.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines9080848</ArticleId><ArticleId IdType="pmc">PMC8402319</ArticleId><ArticleId IdType="pubmed">34451973</ArticleId></ArticleIdList></Reference><Reference><Citation>Teijaro J.R., Farber D.L. COVID-19 vaccines: Modes of immune activation and future challenges. Nat. Rev. Immunol. 2021;21:195–197. doi: 10.1038/s41577-021-00526-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41577-021-00526-x</ArticleId><ArticleId IdType="pmc">PMC7934118</ArticleId><ArticleId IdType="pubmed">33674759</ArticleId></ArticleIdList></Reference><Reference><Citation>Boyd M.A.A., Carey Hoppe A., Kelleher A.D., Munier C.M.L. T follicular helper cell responses to SARS-CoV-2 vaccination among healthy and immunocompromised adults. Immunol. Cell Biol. 2023;101:504–513. doi: 10.1111/imcb.12635.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/imcb.12635</ArticleId><ArticleId IdType="pmc">PMC10952589</ArticleId><ArticleId IdType="pubmed">36825370</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaech S.M., Wherry E.J., Ahmed R. Effector and memory T-cell differentiation: Implications for vaccine development. Nat. Rev. Immunol. 2002;2:251–262. doi: 10.1038/nri778.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nri778</ArticleId><ArticleId IdType="pubmed">12001996</ArticleId></ArticleIdList></Reference><Reference><Citation>Schoenberger S.P. CD69 guides CD4+T-cells to the seat of memory. Proc. Natl. Acad. Sci. USA. 2012;109:8358–8359. doi: 10.1073/pnas.1204616109.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1204616109</ArticleId><ArticleId IdType="pmc">PMC3365190</ArticleId><ArticleId IdType="pubmed">22615400</ArticleId></ArticleIdList></Reference><Reference><Citation>Pollard A.J., Bijker E.M. A guide to vaccinology: From basic principles to new developments. Nat. Rev. Immunol. 2020;21:83–100. doi: 10.1038/s41577-020-00479-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41577-020-00479-7</ArticleId><ArticleId IdType="pmc">PMC7754704</ArticleId><ArticleId IdType="pubmed">33353987</ArticleId></ArticleIdList></Reference><Reference><Citation>Bertoletti A., Le Bert N., Qui M., Tan A.T. SARS-CoV-2-specific T-cells in infection and vaccination. Cell. Mol. Immunol. 2021;18:2307–2312. doi: 10.1038/s41423-021-00743-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41423-021-00743-3</ArticleId><ArticleId IdType="pmc">PMC8408362</ArticleId><ArticleId IdType="pubmed">34471260</ArticleId></ArticleIdList></Reference><Reference><Citation>Oberhardt V., Luxenburger H., Kemming J., Schulien I., Ciminski K., Giese S., Csernalabics B., Lang-Meli J., Janowska I., Staniek J., et al. Rapid and stable mobilization of CD8+ T-cells by SARS-CoV-2 mRNA vaccine. Nature. 2021;597:268–273. doi: 10.1038/s41586-021-03841-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03841-4</ArticleId><ArticleId IdType="pmc">PMC8426185</ArticleId><ArticleId IdType="pubmed">34320609</ArticleId></ArticleIdList></Reference><Reference><Citation>Painter M.M., Mathew D., Goel R.R., Apostolidis S.A., Pattekar A., Kuthuru O., Baxter A.E., Herati R.S., Oldridge D.A., Gouma S., et al. Rapid induction of antigen-specific CD4+ T-cells is associated with coordinated humoral and cellular immunity to SARS-CoV-2 mRNA vaccination. Immunity. 2021;54:2133–2142.e2133. doi: 10.1016/j.immuni.2021.08.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2021.08.001</ArticleId><ArticleId IdType="pmc">PMC8361141</ArticleId><ArticleId IdType="pubmed">34453880</ArticleId></ArticleIdList></Reference><Reference><Citation>Goel R.R., Painter M.M., Apostolidis S.A., Mathew D., Meng W., Rosenfeld A.M., Lundgreen K.A., Reynaldi A., Khoury D.S., Pattekar A., et al. mRNA vaccines induce durable immune memory to SARS-CoV-2 and variants of concern. Science. 2021;374:abm0829. doi: 10.1126/science.abm0829.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abm0829</ArticleId><ArticleId IdType="pmc">PMC9284784</ArticleId><ArticleId IdType="pubmed">34648302</ArticleId></ArticleIdList></Reference><Reference><Citation>Tarke A., Sidney J., Methot N., Yu E.D., Zhang Y., Dan J.M., Goodwin B., Rubiro P., Sutherland A., Wang E., et al. Impact of SARS-CoV-2 variants on the total CD4+ and CD8+ T cell reactivity in infected or vaccinated individuals. Cell Rep. Med. 2021;2:100355. doi: 10.1016/j.xcrm.2021.100355.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.xcrm.2021.100355</ArticleId><ArticleId IdType="pmc">PMC8249675</ArticleId><ArticleId IdType="pubmed">34230917</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao Y., Cai C., Grifoni A., Müller T.R., Niessl J., Olofsson A., Humbert M., Hansson L., Österborg A., Bergman P., et al. Ancestral SARS-CoV-2-specific T-cells cross-recognize the Omicron variant. Nat. Med. 2022;28:472–476. doi: 10.1038/s41591-022-01700-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-022-01700-x</ArticleId><ArticleId IdType="pmc">PMC8938268</ArticleId><ArticleId IdType="pubmed">35042228</ArticleId></ArticleIdList></Reference><Reference><Citation>Reinscheid M., Luxenburger H., Karl V., Graeser A., Giese S., Ciminski K., Reeg D.B., Oberhardt V., Roehlen N., Lang-Meli J., et al. COVID-19 mRNA booster vaccine induces transient CD8+ T effector cell responses while conserving the memory pool for subsequent reactivation. Nat. Commun. 2022;13:4631. doi: 10.1038/s41467-022-32324-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-022-32324-x</ArticleId><ArticleId IdType="pmc">PMC9358914</ArticleId><ArticleId IdType="pubmed">35941157</ArticleId></ArticleIdList></Reference><Reference><Citation>Mateus J., Dan J.M., Zhang Z., Rydyznski Moderbacher C., Lammers M., Goodwin B., Sette A., Crotty S., Weiskopf D. Low-dose mRNA-1273 COVID-19 vaccine generates durable memory enhanced by cross-reactive T-cells. Science. 2021;374:eabj9853. doi: 10.1126/science.abj9853.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abj9853</ArticleId><ArticleId IdType="pmc">PMC8542617</ArticleId><ArticleId IdType="pubmed">34519540</ArticleId></ArticleIdList></Reference><Reference><Citation>Guerrera G., Picozza M., D’Orso S., Placido R., Pirronello M., Verdiani A., Termine A., Fabrizio C., Giannessi F., Sambucci M., et al. BNT162b2 vaccination induces durable SARS-CoV-2–specific T-cells with a stem cell memory phenotype. Sci. Immunol. 2021;6:eabl5344. doi: 10.1126/sciimmunol.abl5344.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciimmunol.abl5344</ArticleId><ArticleId IdType="pubmed">34726470</ArticleId></ArticleIdList></Reference><Reference><Citation>Payne R.P., Longet S., Austin J.A., Skelly D.T., Dejnirattisai W., Adele S., Meardon N., Faustini S., Al-Taei S., Moore S.C., et al. Immunogenicity of standard and extended dosing intervals of BNT162b2 mRNA vaccine. Cell. 2021;184:5699–5714.e5611. doi: 10.1016/j.cell.2021.10.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2021.10.011</ArticleId><ArticleId IdType="pmc">PMC8519781</ArticleId><ArticleId IdType="pubmed">34735795</ArticleId></ArticleIdList></Reference><Reference><Citation>Crotty S. T Follicular Helper Cell Biology: A Decade of Discovery and Diseases. Immunity. 2019;50:1132–1148. doi: 10.1016/j.immuni.2019.04.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2019.04.011</ArticleId><ArticleId IdType="pmc">PMC6532429</ArticleId><ArticleId IdType="pubmed">31117010</ArticleId></ArticleIdList></Reference><Reference><Citation>Kundu R., Narean J.S., Wang L., Fenn J., Pillay T., Fernandez N.D., Conibear E., Koycheva A., Davies M., Tolosa-Wright M., et al. Cross-reactive memory T-cells associate with protection against SARS-CoV-2 infection in COVID-19 contacts. Nat. Commun. 2022;13:80. doi: 10.1038/s41467-021-27674-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-021-27674-x</ArticleId><ArticleId IdType="pmc">PMC8748880</ArticleId><ArticleId IdType="pubmed">35013199</ArticleId></ArticleIdList></Reference><Reference><Citation>Lederer K., Bettini E., Parvathaneni K., Painter M.M., Agarwal D., Lundgreen K.A., Weirick M., Muralidharan K., Castaño D., Goel R.R., et al. Germinal center responses to SARS-CoV-2 mRNA vaccines in healthy and immunocompromised individuals. Cell. 2022;185:1008–1024.e1015. doi: 10.1016/j.cell.2022.01.027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2022.01.027</ArticleId><ArticleId IdType="pmc">PMC8808747</ArticleId><ArticleId IdType="pubmed">35202565</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramasamy M.N.M., Minassian A.M., Ewer K.J., Flaxman A.L., Folegatti P.M., Owens D.R., Voysey M., Aley P.K., Angus B., Babbage G., et al. Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): A single-blind, randomised, controlled, phase 2/3 trial. Lancet. 2021;19:1979–1993. doi: 10.1016/S0140-6736(20)32466-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)32466-1</ArticleId><ArticleId IdType="pmc">PMC7674972</ArticleId><ArticleId IdType="pubmed">33220855</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeewandara C., Kamaladasa A., Pushpakumara P.D., Jayathilaka D., Aberathna I.S., Danasekara D.R.S.R., Guruge D., Ranasinghe T., Dayarathna S., Pathmanathan T., et al. Immune responses to a single dose of the AZD1222/Covishield vaccine in health care workers. Nat. Commun. 2021;12:4617. doi: 10.1038/s41467-021-24579-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-021-24579-7</ArticleId><ArticleId IdType="pmc">PMC8322137</ArticleId><ArticleId IdType="pubmed">34326317</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Z., Xiang T., Liang B., Deng H., Wang H., Feng X., Quan X., Wang X., Li S., Lu S., et al. Characterization of SARS-CoV-2-Specific Humoral and Cellular Immune Responses Induced by Inactivated COVID-19 Vaccines in a Real-World Setting. Front. Immunol. 2021;12:802858. doi: 10.3389/fimmu.2021.802858.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.802858</ArticleId><ArticleId IdType="pmc">PMC8727357</ArticleId><ArticleId IdType="pubmed">35003131</ArticleId></ArticleIdList></Reference><Reference><Citation>Keech C., Albert G., Cho I., Robertson A., Reed P., Neal S., Plested J.S., Zhu M., Cloney-Clark S., Zhou H., et al. Phase 1–2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine. N. Engl. J. Med. 2020;383:2320–2332. doi: 10.1056/NEJMoa2026920.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2026920</ArticleId><ArticleId IdType="pmc">PMC7494251</ArticleId><ArticleId IdType="pubmed">32877576</ArticleId></ArticleIdList></Reference><Reference><Citation>Hielscher F., Schmidt T., Klemis V., Wilhelm A., Marx S., Abu-Omar A., Ziegler L., Guckelmus C., Urschel R., Sester U., et al. NVX-CoV2373-induced cellular and humoral immunity towards parental SARS-CoV-2 and VOCs compared to BNT162b2 and mRNA-1273-regimens. J. Clin. Virol. 2022;157:105321. doi: 10.1016/j.jcv.2022.105321.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcv.2022.105321</ArticleId><ArticleId IdType="pmc">PMC9576915</ArticleId><ArticleId IdType="pubmed">36279695</ArticleId></ArticleIdList></Reference><Reference><Citation>Cho A., Muecksch F., Schaefer-Babajew D., Wang Z., Finkin S., Gaebler C., Ramos V., Cipolla M., Mendoza P., Agudelo M., et al. Anti-SARS-CoV-2 receptor-binding domain antibody evolution after mRNA vaccination. Nature. 2021;600:517–522. doi: 10.1038/s41586-021-04060-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-04060-7</ArticleId><ArticleId IdType="pmc">PMC8674133</ArticleId><ArticleId IdType="pubmed">34619745</ArticleId></ArticleIdList></Reference><Reference><Citation>Goel R.R., Painter M.M., Lundgreen K.A., Apostolidis S.A., Baxter A.E., Giles J.R., Mathew D., Pattekar A., Reynaldi A., Khoury D.S., et al. Efficient recall of Omicron-reactive B cell memory after a third dose of SARS-CoV-2 mRNA vaccine. Cell. 2022;185:1875–1887.e1878. doi: 10.1016/j.cell.2022.04.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2022.04.009</ArticleId><ArticleId IdType="pmc">PMC8989683</ArticleId><ArticleId IdType="pubmed">35523182</ArticleId></ArticleIdList></Reference><Reference><Citation>Israel A., Shenhar Y., Green I., Merzon E., Golan-Cohen A., Schäffer A.A., Ruppin E., Vinker S., Magen E. Large-Scale Study of Antibody Titer Decay following BNT162b2 mRNA Vaccine or SARS-CoV-2 Infection. Vaccines. 2021;10:64. doi: 10.3390/vaccines10010064.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines10010064</ArticleId><ArticleId IdType="pmc">PMC8781423</ArticleId><ArticleId IdType="pubmed">35062724</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim W., Zhou J.Q., Horvath S.C., Schmitz A.J., Sturtz A.J., Lei T., Liu Z., Kalaidina E., Thapa M., Alsoussi W.B., et al. Germinal centre-driven maturation of B cell response to mRNA vaccination. Nature. 2022;604:141–145. doi: 10.1038/s41586-022-04527-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-04527-1</ArticleId><ArticleId IdType="pmc">PMC9204750</ArticleId><ArticleId IdType="pubmed">35168246</ArticleId></ArticleIdList></Reference><Reference><Citation>Coronavirus (COVID-19) Update: FDA Authorizes Changes to Simplify Use of Bivalent mRNA COVID-19 Vaccines.  [(accessed on 5 January 2024)]; Available online:  https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-changes-simplify-use-bivalent-mrna-covid-19-vaccines.</Citation></Reference><Reference><Citation>Collier A.-R.Y., Miller J., Hachmann N.P., McMahan K., Liu J., Bondzie E.A., Gallup L., Rowe M., Schonberg E., Thai S., et al. Immunogenicity of BA.5 Bivalent mRNA Vaccine Boosters. N. Engl. J. Med. 2023;388:565–567. doi: 10.1056/NEJMc2213948.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc2213948</ArticleId><ArticleId IdType="pmc">PMC9847505</ArticleId><ArticleId IdType="pubmed">36630611</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin D.-Y., Xu Y., Gu Y., Zeng D., Wheeler B., Young H., Sunny S.K., Moore Z. Effectiveness of Bivalent Boosters against Severe Omicron Infection. N. Engl. J. Med. 2023;388:764–766. doi: 10.1056/NEJMc2215471.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc2215471</ArticleId><ArticleId IdType="pmc">PMC9933929</ArticleId><ArticleId IdType="pubmed">36734847</ArticleId></ArticleIdList></Reference><Reference><Citation>FDA Takes Action on Updated mRNA COVID-19 Vaccines to Better Protect against Currently Circulating Variants.  [(accessed on 3 December 2023)]; Available online:  https://www.fda.gov/news-events/press-announcements/fda-takes-action-updated-mrna-covid-19-vaccines-better-protect-against-currently-circulating.</Citation></Reference><Reference><Citation>Becerra X., Jha A. Project NextGen—Defeating SARS-CoV-2 and Preparing for the Next Pandemic. N. Engl. J. Med. 2023;9:773–775. doi: 10.1056/NEJMp2307867.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMp2307867</ArticleId><ArticleId IdType="pubmed">37494477</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y., Sánchez-Ovando S., Carolan L., Dowson L., Khvorov A., Jessica Hadiprodjo A., Tseng Y.Y., Delahunty C., Khatami A., Macnish M., et al. Superior immunogenicity of mRNA over adenoviral vectored COVID-19 vaccines reflects B cell dynamics independent of anti-vector immunity: Implications for future pandemic vaccines. Vaccine. 2023;41:7192–7200. doi: 10.1016/j.vaccine.2023.10.034.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2023.10.034</ArticleId><ArticleId IdType="pubmed">37903679</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Z., Mateus J., Coelho C.H., Dan J.M., Moderbacher C.R., Gálvez R.I., Cortes F.H., Grifoni A., Tarke A., Chang J., et al. Humoral and cellular immune memory to four COVID-19 vaccines. Cell. 2022;185:2434–2451.e2417. doi: 10.1016/j.cell.2022.05.022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2022.05.022</ArticleId><ArticleId IdType="pmc">PMC9135677</ArticleId><ArticleId IdType="pubmed">35764089</ArticleId></ArticleIdList></Reference><Reference><Citation>Asano M., Okada H., Itoh Y., Hirata H., Ishikawa K., Yoshida E., Matsui A., Kelly E.J., Shoemaker K., Olsson U., et al. Immunogenicity and safety of AZD1222 (ChAdOx1 nCoV-19) against SARS-CoV-2 in Japan: A double-blind, randomized controlled phase 1/2 trial. Int. J. Infect. Dis. 2022;114:165–174. doi: 10.1016/j.ijid.2021.10.030.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2021.10.030</ArticleId><ArticleId IdType="pmc">PMC8531242</ArticleId><ArticleId IdType="pubmed">34688944</ArticleId></ArticleIdList></Reference><Reference><Citation>Chibwana M.G., Moyo-Gwete T., Kwatra G., Mandolo J., Hermanaus T., Motlou T., Mzindle N., Ayres F., Chaponda M., Tembo G., et al. AstraZeneca COVID-19 vaccine induces robust broadly cross-reactive antibody responses in Malawian adults previously infected with SARS-CoV-2. BMC Med. 2022;20:128. doi: 10.1186/s12916-022-02342-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12916-022-02342-z</ArticleId><ArticleId IdType="pmc">PMC8958481</ArticleId><ArticleId IdType="pubmed">35346184</ArticleId></ArticleIdList></Reference><Reference><Citation>Murillo-Zamora E., Trujillo X., Huerta M., Ríos-Silva M., Lugo-Radillo A., Baltazar-Rodríguez L.M., Mendoza-Cano O. First-generation BNT162b2 and AZD1222 vaccines protect from COVID-19 pneumonia during the Omicron variant emergence. Public Health. 2022;207:105–107. doi: 10.1016/j.puhe.2022.04.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.puhe.2022.04.001</ArticleId><ArticleId IdType="pmc">PMC9020510</ArticleId><ArticleId IdType="pubmed">35594806</ArticleId></ArticleIdList></Reference><Reference><Citation>Luan N., Wang Y., Cao H., Lin K., Liu C. Comparison of immune responses induced by two or three doses of an alum-adjuvanted inactivated SARS-CoV-2 vaccine in mice. J. Med. Virol. 2022;94:2250–2258. doi: 10.1002/jmv.27637.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.27637</ArticleId><ArticleId IdType="pmc">PMC9015325</ArticleId><ArticleId IdType="pubmed">35112364</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu X., Wei D., Xu W., Liu C., Guo W., Li X., Tan W., Liu L., Zhang X., Qu J., et al. Neutralizing activity of BBIBP-CorV vaccine-elicited sera against Beta, Delta and other SARS-CoV-2 variants of concern. Nat. Commun. 2022;13:1788. doi: 10.1038/s41467-022-29477-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-022-29477-0</ArticleId><ArticleId IdType="pmc">PMC8980020</ArticleId><ArticleId IdType="pubmed">35379815</ArticleId></ArticleIdList></Reference><Reference><Citation>Dunkle L.M., Kotloff K.L., Gay C.L., Áñez G., Adelglass J.M., Barrat Hernández A.Q., Harper W.L., Duncanson D.M., McArthur M.A., Florescu D.F., et al. Efficacy and Safety of NVX-CoV2373 in Adults in the United States and Mexico. N. Engl. J. Med. 2022;386:531–543. doi: 10.1056/NEJMoa2116185.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2116185</ArticleId><ArticleId IdType="pmc">PMC8693692</ArticleId><ArticleId IdType="pubmed">34910859</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhiman J.N., Richardson S.I., Lambson B.E., Kgagudi P., Mzindle N., Kaldine H., Crowther C., Gray G., Bekker L.-G., Koen A., et al. Novavax NVX-COV2373 triggers neutralization of Omicron sub-lineages. Sci. Rep. 2023;13:1222. doi: 10.1038/s41598-023-27698-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-023-27698-x</ArticleId><ArticleId IdType="pmc">PMC9867547</ArticleId><ArticleId IdType="pubmed">36681693</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y., Tong P., Whiteman N., Sanjari Moghaddam A., Zarghami M., Zuiani A., Habibi S., Gautam A., Keerti, Bi C., et al. Immune recall improves antibody durability and breadth to SARS-CoV-2 variants. Sci. Immunol. 2022;7:eabp8328. doi: 10.1126/sciimmunol.abp8328.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciimmunol.abp8328</ArticleId><ArticleId IdType="pmc">PMC9097880</ArticleId><ArticleId IdType="pubmed">35549298</ArticleId></ArticleIdList></Reference><Reference><Citation>Sette A., Crotty S. Immunological memory to SARS-CoV-2 infection and COVID-19 vaccines. Immunol. Rev. 2022;310:27–46. doi: 10.1111/imr.13089.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/imr.13089</ArticleId><ArticleId IdType="pmc">PMC9349657</ArticleId><ArticleId IdType="pubmed">35733376</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldberg Y., Mandel M., Bar-On Y.M., Bodenheimer O., Freedman L.S., Ash N., Alroy-Preis S., Huppert A., Milo R. Protection and Waning of Natural and Hybrid Immunity to SARS-CoV-2. N. Engl. J. Med. 2022;386:2201–2212. doi: 10.1056/NEJMoa2118946.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2118946</ArticleId><ArticleId IdType="pmc">PMC9165562</ArticleId><ArticleId IdType="pubmed">35613036</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodda L.B., Morawski P.A., Pruner K.B., Fahning M.L., Howard C.A., Franko N., Logue J., Eggenberger J., Stokes C., Golez I., et al. Imprinted SARS-CoV-2-specific memory lymphocytes define hybrid immunity. Cell. 2022;185:1588–1601.e1514. doi: 10.1016/j.cell.2022.03.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2022.03.018</ArticleId><ArticleId IdType="pmc">PMC8926873</ArticleId><ArticleId IdType="pubmed">35413241</ArticleId></ArticleIdList></Reference><Reference><Citation>Bowman K.A., Stein D., Shin S., Ferbas K.G., Tobin N.H., Mann C., Fischinger S., Ollmann Saphire E., Lauffenburger D., Rimoin A.W., et al. Hybrid Immunity Shifts the Fc-Effector Quality of SARS-CoV-2 mRNA Vaccine-Induced Immunity. mBio. 2022;13:e01647-22. doi: 10.1128/mbio.01647-22.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/mbio.01647-22</ArticleId><ArticleId IdType="pmc">PMC9600672</ArticleId><ArticleId IdType="pubmed">36000735</ArticleId></ArticleIdList></Reference><Reference><Citation>Petrone L., Sette A., de Vries R.D., Goletti D. The Importance of Measuring SARS-CoV-2-Specific T-Cell Responses in an Ongoing Pandemic. Pathogens. 2023;12:862.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10385870</ArticleId><ArticleId IdType="pubmed">37513709</ArticleId></ArticleIdList></Reference><Reference><Citation>Reynolds C.J., Pade C., Gibbons J.M., Otter A.D., Lin K.-M., Muñoz Sandoval D., Pieper F.P., Butler D.K., Liu S., Joy G., et al. Immune boosting by B.1.1.529 (Omicron) depends on previous SARS-CoV-2 exposure. Science. 2022;377:eabq1841. doi: 10.1126/science.abq1841.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abq1841</ArticleId><ArticleId IdType="pmc">PMC9210451</ArticleId><ArticleId IdType="pubmed">35699621</ArticleId></ArticleIdList></Reference><Reference><Citation>Jung M.K., Jeong S.D., Noh J.Y., Kim D.-U., Jung S., Song J.Y., Jeong H.W., Park S.-H., Shin E.-C. BNT162b2-induced memory T-cells respond to the Omicron variant with preserved polyfunctionality. Nat. Microbiol. 2022;7:909–917. doi: 10.1038/s41564-022-01123-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41564-022-01123-x</ArticleId><ArticleId IdType="pubmed">35577972</ArticleId></ArticleIdList></Reference><Reference><Citation>Malato J., Ribeiro R.M., Leite P.P., Casaca P., Fernandes E., Antunes C., Fonseca V.R., Gomes M.C., Graca L. Risk of BA.5 Infection among Persons Exposed to Previous SARS-CoV-2 Variants. N. Engl. J. Med. 2022;387:953–954. doi: 10.1056/NEJMc2209479.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc2209479</ArticleId><ArticleId IdType="pmc">PMC9454644</ArticleId><ArticleId IdType="pubmed">36044619</ArticleId></ArticleIdList></Reference><Reference><Citation>Altarawneh H.N., Chemaitelly H., Ayoub H.H., Tang P., Hasan M.R., Yassine H.M., Al-Khatib H.A., Smatti M.K., Coyle P., Al-Kanaani Z., et al. Effects of Previous Infection and Vaccination on Symptomatic Omicron Infections. N. Engl. J. Med. 2022;387:21–34. doi: 10.1056/NEJMoa2203965.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2203965</ArticleId><ArticleId IdType="pmc">PMC9258753</ArticleId><ArticleId IdType="pubmed">35704396</ArticleId></ArticleIdList></Reference><Reference><Citation>Townsend J.P., Hassler H.B., Wang Z., Miura S., Singh J., Kumar S., Ruddle N.H., Galvani A.P., Dornburg A. The durability of immunity against reinfection by SARS-CoV-2: A comparative evolutionary study. Lancet Microbe. 2021;12:666–675. doi: 10.1016/S2666-5247(21)00219-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2666-5247(21)00219-6</ArticleId><ArticleId IdType="pmc">PMC8486316</ArticleId><ArticleId IdType="pubmed">34632431</ArticleId></ArticleIdList></Reference><Reference><Citation>Stegger M., Edslev S.M., Sieber R.N., Cäcilia Ingham A., Ng K.L., Tang M.-H.E., Alexandersen S., Fonager J., Legarth R., Utko M., et al. Occurrence and significance of Omicron BA. 1 infection followed by BA. 2 reinfection. MedRxiv. 2022 doi: 10.1101/2022.02.19.22271112. preprint .</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2022.02.19.22271112</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo L., Zhang Q., Gu X., Ren L., Huang T., Li Y., Zhang H., Liu Y., Zhong J., Wang X., et al. Durability and cross-reactive immune memory to SARS-CoV-2 in individuals 2 years after recovery from COVID-19: A longitudinal cohort study. Lancet Microbe. 2024;5:e24–e33. doi: 10.1016/S2666-5247(23)00255-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2666-5247(23)00255-0</ArticleId><ArticleId IdType="pmc">PMC10789611</ArticleId><ArticleId IdType="pubmed">38048805</ArticleId></ArticleIdList></Reference><Reference><Citation>Zuo F., Abolhassani H., Du L., Piralla A., Bertoglio F., de Campos-Mata L., Wan H., Schubert M., Cassaniti I., Wang Y., et al. Heterologous immunization with inactivated vaccine followed by mRNA-booster elicits strong immunity against SARS-CoV-2 Omicron variant. Nat. Commun. 2022;13:2670. doi: 10.1038/s41467-022-30340-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-022-30340-5</ArticleId><ArticleId IdType="pmc">PMC9106736</ArticleId><ArticleId IdType="pubmed">35562366</ArticleId></ArticleIdList></Reference><Reference><Citation>Ho P.L., Cervantes-Luevano K., Espino-Vazquez A.N., Flores-Acosta G., Bernaldez-Sarabia J., Cabanillas-Bernal O., Gasperin-Bulbarela J., Gonzalez-Sanchez R., Comas-Garcia A., Licea-Navarro A.F. Neutralizing antibodies levels are increased in individuals with heterologous vaccination and hybrid immunity with Ad5-nCoV in the north of Mexico. PLoS ONE. 2022;17:e0269032. doi: 10.1371/journal.pone.0269032.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0269032</ArticleId><ArticleId IdType="pmc">PMC9231729</ArticleId><ArticleId IdType="pubmed">35749390</ArticleId></ArticleIdList></Reference><Reference><Citation>Zimmermann P., Curtis N. Factors That Influence the Immune Response to Vaccination. Clin. Microbiol. Rev. 2019;32:e00084-18. doi: 10.1128/CMR.00084-18.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/CMR.00084-18</ArticleId><ArticleId IdType="pmc">PMC6431125</ArticleId><ArticleId IdType="pubmed">30867162</ArticleId></ArticleIdList></Reference><Reference><Citation>Fish E.N. The X-files in immunity: Sex-based differences predispose immune responses. Nat. Rev. Immunol. 2008;8:737–744. doi: 10.1038/nri2394.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nri2394</ArticleId><ArticleId IdType="pmc">PMC7097214</ArticleId><ArticleId IdType="pubmed">18728636</ArticleId></ArticleIdList></Reference><Reference><Citation>Fonseca M.H.G., de Souza T.d.F.G., de Carvalho Araújo F.M., de Andrade L.O.M. Dynamics of antibody response to CoronaVac vaccine. J. Med. Virol. 2022;94:2139–2148. doi: 10.1002/jmv.27604.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.27604</ArticleId><ArticleId IdType="pmc">PMC9015561</ArticleId><ArticleId IdType="pubmed">35060174</ArticleId></ArticleIdList></Reference><Reference><Citation>Lustig Y., Sapir E., Regev-Yochay G., Cohen C., Fluss R., Olmer L., Indenbaum V., Mandelboim M., Doolman R., Amit S., et al. BNT162b2 COVID-19 vaccine and correlates of humoral immune responses and dynamics: A prospective, single-centre, longitudinal cohort study in health-care workers. Lancet Respir. Med. 2021;9:999–1009. doi: 10.1016/S2213-2600(21)00220-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(21)00220-4</ArticleId><ArticleId IdType="pmc">PMC8253545</ArticleId><ArticleId IdType="pubmed">34224675</ArticleId></ArticleIdList></Reference><Reference><Citation>Fujigaki H.Y., Yamamoto Y., Koseki T., Banno S., Ando T., Ito H., Fujita T., Naruse H., Hata T., Moriyama S., et al. Antibody Responses to BNT162b2 Vaccination in Japan: Monitoring Vaccine Efficacy by Measuring IgG Antibodies against the Receptor-Binding Domain of SARS-CoV-2. Microbiol. Spectr. 2022;23 doi: 10.1128/spectrum.01181-21.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/spectrum.01181-21</ArticleId><ArticleId IdType="pmc">PMC8768797</ArticleId><ArticleId IdType="pubmed">35044205</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie J., Mothe B., Alcalde Herraiz M., Li C., Xu Y., Jödicke A.M., Gao Y., Wang Y., Feng S., Wei J., et al. Relationship between HLA genetic variations, COVID-19 vaccine antibody response, and risk of breakthrough outcomes. Nat. Commun. 2024;15:4031. doi: 10.1038/s41467-024-48339-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-024-48339-5</ArticleId><ArticleId IdType="pmc">PMC11091043</ArticleId><ArticleId IdType="pubmed">38740772</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolday D., Fung C.Y.J., Morgan G., Casalino S., Frangione E., Taher J., Lerner-Ellis J.P. HLA Variation and SARS-CoV-2 Specific Antibody Response. Viruses. 2023;15:906. doi: 10.3390/v15040906.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v15040906</ArticleId><ArticleId IdType="pmc">PMC10143129</ArticleId><ArticleId IdType="pubmed">37112884</ArticleId></ArticleIdList></Reference><Reference><Citation>Fernandes M.d.C.R., Vasconcelos G.S., de Melo A.C.L., Matsui T.C., Caetano L.F., de Carvalho Araújo F.M., Fonseca M.H.G. Influence of age, gender, previous SARS-CoV-2 infection, and pre-existing diseases in antibody response after COVID-19 vaccination: A review. Mol. Immunol. 2023;156:148–155. doi: 10.1016/j.molimm.2023.03.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molimm.2023.03.007</ArticleId><ArticleId IdType="pmc">PMC9998295</ArticleId><ArticleId IdType="pubmed">36921489</ArticleId></ArticleIdList></Reference><Reference><Citation>Figueiredo J.C., Merin N.M., Hamid O., Choi S.Y., Lemos T., Cozen W., Nguyen N., Finster L.J., Foley J., Darrah J., et al. Longitudinal SARS-CoV-2 mRNA Vaccine-Induced Humoral Immune Responses in Patients with Cancer. Cancer Res. 2021;81:6273–6280. doi: 10.1158/0008-5472.CAN-21-3554.</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/0008-5472.CAN-21-3554</ArticleId><ArticleId IdType="pmc">PMC9060668</ArticleId><ArticleId IdType="pubmed">34759001</ArticleId></ArticleIdList></Reference><Reference><Citation>Linardou H., Spanakis N., Koliou G.-A., Christopoulou A., Karageorgopoulou S., Alevra N., Vagionas A., Tsoukalas N., Sgourou S., Fountzilas E., et al. Responses to SARS-CoV-2 Vaccination in Patients with Cancer (ReCOVer Study): A Prospective Cohort Study of the Hellenic Cooperative Oncology Group. Cancers. 2021;13:4621. doi: 10.3390/cancers13184621.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cancers13184621</ArticleId><ArticleId IdType="pmc">PMC8466969</ArticleId><ArticleId IdType="pubmed">34572848</ArticleId></ArticleIdList></Reference><Reference><Citation>Gounant V., Ferré V.M., Soussi G., Charpentier C., Flament H., Fidouh N., Collin G., Namour C., Assoun S., Bizot A., et al. Efficacy of Severe Acute Respiratory Syndrome Coronavirus-2 Vaccine in Patients With Thoracic Cancer: A Prospective Study Supporting a Third Dose in Patients With Minimal Serologic Response After Two Vaccine Doses. J. Thorac. Oncol. 2022;17:239–251. doi: 10.1016/j.jtho.2021.10.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jtho.2021.10.015</ArticleId><ArticleId IdType="pmc">PMC8593625</ArticleId><ArticleId IdType="pubmed">34798306</ArticleId></ArticleIdList></Reference><Reference><Citation>Ito E., Bachelet T., Bourdenx J.-P., Martinez C., Mucha S., Martin-Dupont P., Perier V., Pommereau A. Humoral response after SARS-CoV-2 mRNA vaccines in dialysis patients: Integrating anti-SARS-CoV-2 Spike-Protein-RBD antibody monitoring to manage dialysis centers in pandemic times. PLoS ONE. 2021;16:e0257646. doi: 10.1371/journal.pone.0257646.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0257646</ArticleId><ArticleId IdType="pmc">PMC8491898</ArticleId><ArticleId IdType="pubmed">34610031</ArticleId></ArticleIdList></Reference><Reference><Citation>Duni A., Markopoulos G.S., Mallioras I., Pappas H., Pappas E., Koutlas V., Tzalavra E., Baxevanos G., Priska S., Gartzonika K., et al. The Humoral Immune Response to BNT162b2 Vaccine Is Associated With Circulating CD19+ B Lymphocytes and the Naïve CD45RA to Memory CD45RO CD4+ T Helper Cells Ratio in Hemodialysis Patients and Kidney Transplant Recipients. Front. Immunol. 2021;12:760249. doi: 10.3389/fimmu.2021.760249.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.760249</ArticleId><ArticleId IdType="pmc">PMC8678464</ArticleId><ArticleId IdType="pubmed">34925330</ArticleId></ArticleIdList></Reference><Reference><Citation>Weigert A., Bergman M.-L., Gonçalves L.A., Godinho I., Duarte N., Abrantes R., Borges P., Brennand A., Malheiro V., Matoso P., et al. Longitudinal Analysis of Antibody Responses to the mRNA BNT162b2 Vaccine in Patients Undergoing Maintenance Hemodialysis: A 6-Month Follow-Up. Front. Med. 2021;8:796676. doi: 10.3389/fmed.2021.796676.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2021.796676</ArticleId><ArticleId IdType="pmc">PMC8740691</ArticleId><ArticleId IdType="pubmed">35004771</ArticleId></ArticleIdList></Reference><Reference><Citation>Dębska-Ślizień A., Ślizień Z., Muchlado M., Kubanek A., Piotrowska M., Dąbrowska M., Tarasewicz A., Chamienia A., Biedunkiewicz B., Renke M., et al. Predictors of Humoral Response to mRNA COVID19 Vaccines in Kidney Transplant Recipients: A Longitudinal Study—The COViNEPH Project. Vaccines. 2021;9:1165. doi: 10.3390/vaccines9101165.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines9101165</ArticleId><ArticleId IdType="pmc">PMC8540727</ArticleId><ArticleId IdType="pubmed">34696273</ArticleId></ArticleIdList></Reference><Reference><Citation>Guarino M., Esposito I., Portella G., Cossiga V., Loperto I., Pignata L., Tortora R., Attanasio M.R., Cennamo M., Capasso M., et al. Humoral response to 2-dose BNT162b2 mRNA vaccine for Covid-19 in liver transplant recipients. Dig. Liver Dis. 2022;54:S19. doi: 10.1016/j.dld.2022.01.035.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.dld.2022.01.035</ArticleId><ArticleId IdType="pmc">PMC8770248</ArticleId><ArticleId IdType="pubmed">35066136</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang A., Cicin-Sain C., Pasin C., Epp S., Audigé A., Müller N.J., Nilsson J., Bankova A., Wolfensberger N., Vilinovszki O., et al. Antibody Response to SARS-CoV-2 Vaccination in Patients following Allogeneic Hematopoietic Cell Transplantation. Transplant. Cell. Ther. 2022;28:e211–e214. doi: 10.1016/j.jtct.2022.01.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jtct.2022.01.019</ArticleId><ArticleId IdType="pmc">PMC8802693</ArticleId><ArticleId IdType="pubmed">35092892</ArticleId></ArticleIdList></Reference><Reference><Citation>Tylicki L., Dębska-Ślizień A., Muchlado M., Ślizień Z., Gołębiewska J., Dąbrowska M., Biedunkiewicz B. Boosting Humoral Immunity from mRNA COVID-19 Vaccines in Kidney Transplant Recipients. Vaccines. 2021;10:56. doi: 10.3390/vaccines10010056.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines10010056</ArticleId><ArticleId IdType="pmc">PMC8779302</ArticleId><ArticleId IdType="pubmed">35062717</ArticleId></ArticleIdList></Reference><Reference><Citation>Razonable R.R. Corrigendum: Protecting the vulnerable: Addressing the COVID-19 care needs of people with compromised immunity. Front. Immunol. 2024;15:1440571. doi: 10.3389/fimmu.2024.1440571.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2024.1440571</ArticleId><ArticleId IdType="pmc">PMC11307124</ArticleId><ArticleId IdType="pubmed">39119333</ArticleId></ArticleIdList></Reference><Reference><Citation>Suryawanshi R., Ott M. SARS-CoV-2 hybrid immunity: Silver bullet or silver lining? Nat. Rev. Immunol. 2022;22:591–592. doi: 10.1038/s41577-022-00771-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41577-022-00771-8</ArticleId><ArticleId IdType="pmc">PMC9362961</ArticleId><ArticleId IdType="pubmed">35945353</ArticleId></ArticleIdList></Reference><Reference><Citation>Yisimayi A., Song W., Wang J., Jian F., Yu Y., Chen X., Xu Y., Yang S., Niu X., Xiao T., et al. Repeated Omicron exposures override ancestral SARS-CoV-2 immune imprinting. Nature. 2023;625:148–156. doi: 10.1038/s41586-023-06753-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-023-06753-7</ArticleId><ArticleId IdType="pmc">PMC10764275</ArticleId><ArticleId IdType="pubmed">37993710</ArticleId></ArticleIdList></Reference><Reference><Citation>Qui M., Hariharaputran S., Hang S.K., Zhang J., Tan C.W., Chong C.Y., Low J., Wang L., Bertoletti A., Yung C.F., et al. T cell hybrid immunity against SARS-CoV-2 in children: A longitudinal study. eBioMedicine. 2024;105:105203. doi: 10.1016/j.ebiom.2024.105203.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ebiom.2024.105203</ArticleId><ArticleId IdType="pmc">PMC11237860</ArticleId><ArticleId IdType="pubmed">38896919</ArticleId></ArticleIdList></Reference><Reference><Citation>Swadling L., Diniz M.O., Schmidt N.M., Amin O.E., Chandran A., Shaw E., Pade C., Gibbons J.M., Le Bert N., Tan A.T., et al. Pre-existing polymerase-specific T-cells expand in abortive seronegative SARS-CoV-2. Nature. 2021;601:110–117. doi: 10.1038/s41586-021-04186-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-04186-8</ArticleId><ArticleId IdType="pmc">PMC8732273</ArticleId><ArticleId IdType="pubmed">34758478</ArticleId></ArticleIdList></Reference><Reference><Citation>Ssemaganda A., Nguyen H.M., Nuhu F., Jahan N., Card C.M., Kiazyk S., Severini G., Keynan Y., Su R.-C., Ji H., et al. Expansion of cytotoxic tissue-resident CD8+ T-cells and CCR6+CD161+ CD4+ T-cells in the nasal mucosa following mRNA COVID-19 vaccination. Nat. Commun. 2022;13:3357. doi: 10.1038/s41467-022-30913-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-022-30913-4</ArticleId><ArticleId IdType="pmc">PMC9186487</ArticleId><ArticleId IdType="pubmed">35688805</ArticleId></ArticleIdList></Reference><Reference><Citation>McMahan K., Wegmann F., Aid M., Sciacca M., Liu J., Hachmann N.P., Miller J., Jacob-Dolan C., Powers O., Hope D., et al. Mucosal boosting enhances vaccine protection against SARS-CoV-2 in macaques. Nature. 2023;626:385–391. doi: 10.1038/s41586-023-06951-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-023-06951-3</ArticleId><ArticleId IdType="pmc">PMC10849944</ArticleId><ArticleId IdType="pubmed">38096903</ArticleId></ArticleIdList></Reference><Reference><Citation>Netea M.G., Ziogas A., Benn C.S., Giamarellos-Bourboulis E.J., Joosten L.A.B., Arditi M., Chumakov K., van Crevel R., Gallo R., Aaby P., et al. The role of trained immunity in COVID-19: Lessons for the next pandemic. Cell Host Microbe. 2023;31:890–901. doi: 10.1016/j.chom.2023.05.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chom.2023.05.004</ArticleId><ArticleId IdType="pmc">PMC10265767</ArticleId><ArticleId IdType="pubmed">37321172</ArticleId></ArticleIdList></Reference><Reference><Citation>Bayram Z., Musharrafieh U., Bizri A.R. Revisiting the potential role of BCG and MMR vaccines in COVID-19. Sci. Prog. 2022;105:003685042211051. doi: 10.1177/00368504221105172.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/00368504221105172</ArticleId><ArticleId IdType="pmc">PMC10450304</ArticleId><ArticleId IdType="pubmed">35848578</ArticleId></ArticleIdList></Reference><Reference><Citation>Hall V.G., Ferreira V.H., Wood H., Ierullo M., Majchrzak-Kita B., Manguiat K., Robinson A., Kulasingam V., Humar A., Kumar D. Delayed-interval BNT162b2 mRNA COVID-19 vaccination enhances humoral immunity and induces robust T cell responses. Nat. Immunol. 2022;23:380–385. doi: 10.1038/s41590-021-01126-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-021-01126-6</ArticleId><ArticleId IdType="pubmed">35115679</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanchez S., Palacio N., Dangi T., Ciucci T., Penaloza-MacMaster P. Fractionating a COVID-19 Ad5-vectored vaccine improves virus-specific immunity. Sci. Immunol. 2021;6:eabi8635. doi: 10.1126/sciimmunol.abi8635.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciimmunol.abi8635</ArticleId><ArticleId IdType="pmc">PMC9278052</ArticleId><ArticleId IdType="pubmed">34648369</ArticleId></ArticleIdList></Reference><Reference><Citation>Qian F.-H., Cao Y., Liu Y.-X., Huang J., Zhu R.-H. A predictive model to explore risk factors for severe COVID-19. Sci. Rep. 2024;14:18197. doi: 10.1038/s41598-024-68946-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-024-68946-y</ArticleId><ArticleId IdType="pmc">PMC11303808</ArticleId><ArticleId IdType="pubmed">39107340</ArticleId></ArticleIdList></Reference><Reference><Citation>Rouzine I.M., Rozhnova G. Evolutionary implications of SARS-CoV-2 vaccination for the future design of vaccination strategies. Commun. Med. 2023;3:86. doi: 10.1038/s43856-023-00320-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s43856-023-00320-x</ArticleId><ArticleId IdType="pmc">PMC10279745</ArticleId><ArticleId IdType="pubmed">37336956</ArticleId></ArticleIdList></Reference><Reference><Citation>Cankat S., Demael M.U., Swadling L. In search of a pan-coronavirus vaccine: Next-generation vaccine design and immune mechanisms. Cell. Mol. Immunol. 2023;21:103–118. doi: 10.1038/s41423-023-01116-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41423-023-01116-8</ArticleId><ArticleId IdType="pmc">PMC10805787</ArticleId><ArticleId IdType="pubmed">38148330</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>